Introduction
In the classical paradigm of G protein-coupled receptor (GPCR) signaling, agonist stimulation of seven transmembrane spanning GPCRs leads to the rapid exchange of GDP for GTP on the a subunit of the heterotrimeric G proteins and the subsequent dissociation of the a and bg subunits. Both the a and bg subunits go on to activate a number of dierent eectors, including second messenger generating systems such as adenylyl cyclase and phospholipase C. Until recently, models of GPCR signaling have been exclusively based on these classical second messenger generating systems. However, these models do not adequately explain the full range of eects of GPCR stimulation, especially on cell growth and dierentiation. There has been growing realization that these biological processes are dependent on GPCR mediated stimulation of a large number of complex cascades which ultimately lead to activation of mitogen activated protein kinases (MAPKs). Here, we review recently discovered mechanisms by which GPCRs activate MAPKs, focusing on several novel and intertwined aspects of this activation. These include the roles of receptor and non-receptor tyrosine kinases, internalization (endocytosis), and scaolding in the activation of various MAPKs.
Receptor tyrosine kinase transactivation
Current understanding of the mechanisms by which cell surface receptors activate MAPKs, especially the Extracellular Signal Regulated Kinases (ERKs), is founded upon study of classical receptor tyrosine kinases such as the Epidermal Growth Factor Receptor (EGFR). Following agonist stimulation, these receptors, which contain a single transmembrane spanning domain, dimerize and transphosphorylate tyrosines within their cytoplasmic domains. Tyrosine phosphorylation of the EGFR leads to the recruitment of other signaling proteins including phospholipase Cg and the non-receptor tyrosine kinase c-Src. EGFR activation also leads to tyrosine phosphorylation of the adapter protein SHC, and the association of SHC and Grb2 with the EGFR. Grb2 is constitutively associated with the Ras-guanine nucleotide exchange factor, Sos1, which catalyzes the exchange of GTP for GDP on Ras. Ras, in turn, initiates a phosphorylation cascade consisting of a MAPK kinase kinase (MAPKKK) (Raf), a MAPK kinase (MAPKK) (MEK) and a MAPK (ERK) (Figure 1) .
Like the RTKs, stimulation of many heptahelical receptors leads to the rapid activation of the ERK pathway. Surprisingly, the pathways of GPCR and RTK mediated ERK activation are in many cases convergent. Both pathways involve tyrosine phosphorylation of SHC and also Ras activation (Chen et al., 1996; van Biesen et al., 1995; Winitz et al., 1993) . The basis for the convergence became apparent when it was found that, in addition to the tyrosine phosphorylation of SHC, GPCR stimulation actually leads to tyrosine phosphorylation of RTKs, such as the EGFR, a process that has become known as`transactivation' (Daub et al., 1996 Luttrell et al., 1997b) (Figure  1 ). Following tyrosine phosphorylation of the EGFR, GPCR and EGFR mediated ERK activation are indistinguishable, and inhibiting the intrinsic EGFR tyrosine kinase activity blocks both EGFR and GPCR mediated ERK activation . Thus, in a sense GPCRs`hijack' the ERK kinase cascade normally used by RTKs.
While the steps downstream of RTK tyrosine phosphorylation are quite well understood, the steps leading from GPCR stimulation to RTK tyrosine phosphorylation and activation are less clear. One important question has been whether or not transactivation involves the release of an RTK ligand. Initial evidence suggested that transactivation was probably ligand independent. First, the time course of GPCR mediated RTK tyrosine phosphorylation is quite rapid, occurring within 2 min after GPCR stimulation (Daub et al., 1996) . Second, experiments designed to detect the release of EGF into the extracellular media following GPCR stimulation were initially unsuccessful (Tsai et al., 1997) .
Recently Prenzel et al. (1999) have elegantly established that stimulation of GPCRs, including thrombin receptors, LPA receptors, bombesin receptors and endothelin receptors, can lead to the release, or shedding, of an EGFR ligand, heparin binding EGF (HB ± EGF). GPCR stimulated tyrosine phosphorylation of the EGFR can be blocked by both selective inhibitors of HB ± EGF (CRM 197, a non-toxic diphtheria toxin analog) and also a non-selective matrix metalloprotease inhibitor, batimastat. Thus, through unknown mechanisms, activation of a GPCR leads to the rapid activation of a metalloprotease that in turn leads to the release of HB ± EGF (Figure 1 ). This HB ± EGF acts in an autocrine/paracrine manner to activate the EGFR, which ultimately results in ERK activation. This same mechanism of HB ± EGF shedding is responsible for EGFR transactivation via endogenous angiotensin receptors in vascular smooth muscle cells (Kalmes et al., 2000) .
Currently, both the identity of the metalloprotease and the early steps leading to the activation of the metalloprotease are unknown. In several studies, Gbg subunits (Luttrell et al., 1997b) , increases in intracellular calcium (Keely et al., 1998; Zwick et al., 1997) , cSrc activation (Keely et al., 2000; Luttrell et al., 1997b; Maudsley et al., 2000) , and PYK2 activation (Keely et al., 2000) have all been shown to precede EGFR transactivation. In addition, the data showing that GPCR mediated HB ± EGF shedding can lead to ERK activation in nearby cells has raised questions about the spatial regulation of transactivation in situ. HB ± EGF strongly interacts with cell surface proteoglycans, limiting its ability to diuse large distances (Raab and Klagsbrun, 1997) . Taken together with the rapid time course of transactivation stimulated ERK activation, it is likely that transactivation involves cross talk between receptors which are localized near to each other or even adjacent. In COS-7 cells, agonist stimulation of the b 2 adrenergic receptor (AR) leads to the formation of a complex containing the b 2 AR and the EGFR along with c-Src and b-arrestin1. Whether formation of this complex is the result of the signaling which occurs within discrete microdomains or whether it represents the basis for a novel mechanism of transactivation Figure 1 GPCR mediated transactivation of the EGFR involves HB ± EGF shedding. Agonist stimulation of several GPCRs including thrombin receptors, LPA receptors, muscarinic receptors, and endothelin receptors leads to the activation of an unknown metalloprotease that in turn cleaves proHB-EGF leading to the release or`shedding' of mature HB-EGF (Prenzel et al., 1999) . HB-EGF is able to bind to and activate EGFR either on the same cell or on adjacent cells. Activation of the EGFR leads to a series of phosphorylation events that culminate in the phosphorylation of ERK. To date, the nature and the identity of the metalloprotease and the mechanisms by which GPCR stimulation leads to the rapid activation of the metalloprotease are unknown remains to be determined. However, HB ± EGF shedding is not the only mechanism of transactivation. In addition to the EGFR, GPCRs can transactivate other RTKs including the platelet derived growth factor receptor (PDGFR) (Herrlich et al., 1998) . Since HB ± EGF does not activate the PDGFR, either there must be shedding of ligands selective for the PDGFR or there must be other mechanisms that can explain PDGFR dependent transactivation.
Focal adhesion scaolds
Although RTK transactivation is a common mechanism of GPCR mediated ERK activation, other pathways contribute to GPCR-mediated ERK activation in many cell types. One of these involves the use of integrin-based scaolds, instead of RTKs, as central organizers that link GPCRs to the ERK cascade. Integrins exist as ab heterodimers that cluster at points of contact between the cell membrane and the extracellular matrix called focal adhesions. Integrins, which are single transmembrane spanning receptors, lack intrinsic tyrosine kinase activity. Instead, they serve as scaolds for the formation of multiprotein signaling cascades. Among the proteins that are recruited to these scaolds are non-receptor tyrosine kinases such as the closely related PYK2 and focal adhesion kinase (p125 FAK). These two kinases are rapidly activated following GPCR stimulation. However, the steps leading from GPCR stimulation to PYK2/FAK activation vary depending on the cell type and the GPCR. Regardless of how PYK2/FAK are activated, both pathways require intact focal adhesions. Following the recruitment of PYK2/FAK to integrin dimers and subsequent activation by autophosphorylation, the cascades are analogous to the pathways utilized by RTKs. The activated PYK2/FAK-integrin complex recruits proteins including c-Src, and Grb2-Sos. The recruitment of Grb2-Sos leads to ERK activation via the sequential activation of Ras, Raf and MEK. An interesting question is whether or not there are links between integrin based signaling scaolds and RTK transactivation. Observations suggest that in some cases they are separate , while in other cases they are interconnected, including PYK2 mediated transactivation of the EGFR (Keely et al., 2000) .
One question that has yet to be answered is what determines the particular pathway(s) of ERK activation that will be utilized in a particular cell. Clearly, part of the answer depends upon the particular receptor subtype and on the cell type. For instance, in cells of neuronal origin, such as PC-12 cells, GPCRs primarily utilize a PYK2 dependent pathway to ERK activation, while in Rat-1 ®broblasts, GPCRs activate ERK primarily by RTK transactivation, and in HEK 293 cells both pathways contribute to ERK activation (Della Rocca et al., 1999a) . However, this does not explain all of the variability that is observed. Beyond the heterogeneity between cell lines, there is heterogeneity within cell lines. For instance, in the case of the b 2 AR, in HEK 293 cells, it was reported that ERK activation involves pertussis toxin sensitive G proteins (Daaka et al., 1997) . Subsequently, also in 293 cells, it has been discovered that the b 2 AR can also activate ERK via the adenylyl cyclase stimulatory G-protein, Gs (Schmitt and Stork, 2000) . The relative contribution of these dierent mechanisms to b 2 AR mediated ERK activation vary in dierent isolates of 293 cells and dierent passages of the same isolate of 293 cells. In all of these isolates, the b 2 AR activates ERK to about the same extent, but the extent to which b 2 AR mediated ERK activation is sensitive to pertussis toxin and to EGFR tyrosine kinase inhibitors diers (Pierce et al., unpublished observations). The factors that underlie this heterogeneity are unclear.
Role of endocytosis in ERK activation by GPCRs
Many cell surface receptors including GPCRs and the EGFR internalize via clathrin coated pits. In the case of GPCRs, internalization involves serine/threonine phosphorylation of agonist-occupied receptors on the third intracellular loop and carboxyl tail. Phosphorylation increases the anity of the receptors for barrestins which serve as adapters for proteins including clathrin (Goodman et al., 1996) and AP-2 (Laporte et al., 1999) that are crucial for the formation of clathrin coated pits.
Through not yet understood mechanisms, proteins including the GTPase dynamin facilitate the pinching o of clathrin coated pits that are then brought inside the cell with their cargo. In classic turning o' models of receptor signaling by GPCRs, the recruitment of b-arrestin physically interrupts coupling between the receptor and its cognate heterotrimeric G-protein. Internalization brings the phosphorylated receptor inside the cell and targets it to acidic endosomes where phosphatases dephosphorylate the receptor. The receptor can then be returned to the cell surface, ready once again to signal via classical Gprotein pathways. Thus, internalization has traditionally been thought of as a way of both bringing the receptor away from the cell surface where it signals, and of recycling, and thus resensitizing the receptor so that it can signal once again.
Novel roles of endocytosis in`turning on' signaling, especially turning on ERK activation were ®rst appreciated, not for GPCRs, but rather for the EGFR (Vieira et al., 1996) . In Hela cells, expression of a form of dynamin I with a mutation in the GTPase domain (K44A dynamin I) led to a marked decrease in Epidermal Growth Factor (EGF) dependent ERK activation with no decrease in other EGFR mediated signaling cascades including cell proliferation. Thus, blocking endocytosis aected only a subset of signaling functions carried out by the EGFR. Similar ®ndings were reported for the insulin like growth factor-1 receptor, an RTK of the insulin receptor family (Chow et al., 1998) .
Following the observation that EGFR dependent ERK activation involved endocytosis, experiments were carried out to determine whether GPCR mediated ERK activation might also be dependent on endocytosis. In Rat-1 cells, ERK activation stimulated by endogenously expressed LPA, thrombin and bombesin receptors was sensitive to four dierent chemical inhibitors of endocytosis, concanavalin A, monodansylcadaverine (MDC), potassium depletion and hypertonic sucrose (Luttrell et al., 1997a) . Similar results have been obtained with the b 2 AR. Classically, the b 2 AR is considered a Gs coupled receptor, that when activated, leads to the accumulation of cAMP via stimulation of the heterotrimeric G-protein, Gs. In several cell types, however, b 2 ARs have been shown to mediate Gi dependent ERK activation (Daaka et al., 1997; Zou et al., 1999) . One explanation for the phenomenon may be the ®nding by Daaka et al. (1997) . that cAMP dependent protein kinase (PKA) mediated phosphorylation of the b 2 AR modulates Gprotein speci®city of the receptor leading to receptor coupling with Gi and subsequent ERK activation. This Gi dependent ERK activation by the b 2 AR is sensitive to transfected inhibitors of clathrin mediated endocytosis, including K44A dynamin (Daaka et al., 1998) . Consistent with the ®ndings by Vieira et al. (1996) , all of the steps up to and including both SHC phosphorylation and Raf activation are intact in cells in which clathrin mediated endocytosis is inhibited. More recent studies demonstrate that internalization of activated MEK is required for ERK activation (Kranenburg et al., 1999) .
An important clue to the role of clathrin-mediated endocytosis in ERK activation came from the ®nding that some GPCRs, which do not themselves internalize, such as the m opioid receptor (Whistler and von Zastrow, 1999) and the a 2A AR mediate ERK activation that is sensitive to expression of K44A dynamin. Coupled with ®ndings that EGFRmediated ERK activation is also sensitive to K44A dynamin expression and that b 2 AR mediated Raf activation is intact in the presence of endocytosis inhibitors, these data suggested that it is not the GPCR itself, but rather some downstream component of the signaling cascade that must engage the endoyctic machinery for ERK activation to occur. For instance, in the case of the a 2A AR, under conditions where ERK activation involves EGFR transactivation, ERK activation is also blocked by inhibitors of clathrin mediated endocytosis . Furthermore, treatment of cells with an a 2A AR agonist leads to the internalization of the EGFR, while the a 2A AR remains on the cell surface. Thus, transactivation mediated ERK activation correlates with sensitivity to clathrin mediated endocytosis, suggesting that these two events are part of a single signaling cascade that is independent of GPCR internalization (Figure 2) .
However, a point that is important to stress is that transactivation is only one of a number of pathways by which GPCRs can activate the ERK cascade and many of the other pathways almost certainly do not involve clathrin coated mediated endocytosis. Endocytosis has also been shown to be important for ERK activation by the 5HT 1A receptor (Della Rocca et al., 1999b) , the m1 muscarinic receptor (Vogler et al., 1999) , and the d, k and m opioid receptors (Ignatova et al., 1999; Whistler and von Zastrow, 1999) . On the other hand, inhibiting clathrin-mediated internalization has been shown not to aect ERK activation mediated by the a 2A,B , and C adrenergic receptors (DeGra et al., 1999; Schramm and Limbird, 1999) , the k opioid receptor (Li et al., 1999) , the m3 muscarinic receptor (Budd et al., 1999) and others (Blaukat et al., 1999; Roche et al., 1999; Yang et al., 1999) . The fact that the same receptor expressed in dierent cellular contexts can mediate ERK activation that is alternatively endocytosis dependent or independent argue for the existence of heterogeneity in signaling mechanisms. Dierential contributions of dynamin-dependent signals arising from transactivated EGFRs and endocytosis-independent signals arising from alternative mechanisms may explain these apparent discrepancies.
Mechanisms of c-Src activation by GPCRs
Recruitment and activation of members of the src family of non-receptor tyrosine kinases is an important feature of several GPCR pathways that lead to ERK activation. These include both the transactivation and PYK2 dependent pathways of GPCR mediated ERK activation. For instance, overexpression of c-Src Kinase (CSK), a physiological inhibitor of c-Src activation, impairs Gbg mediated LPA and a 2A AR stimulated tyrosine phosphorylation of the EGFR and SHC (Luttrell et al., 1997b) . In vascular smooth muscle cells, stimulation of angiotensin II type 1 receptors activates c-src via a Gaq and calcium dependent mechanism, upstream of tyrosine phosphorylation of the EGFR (Eguchi et al., 1998) . Interestingly, there is data that, at least in one case, c-Src is involved in transactivation mediated ERK activation, but only downstream of tyrosine phosphorylation of the EGFR . In the PYK2 dependent pathway, mutation of an autophophorylation site of PYK2 that normally binds c-Src prevents GPCR mediated ERK activation as does CSK overexpression (Dikic et al., 1996) .
Recent data have suggested a novel role for the adapter protein b-arrestin in recruiting and activating c-Src (Luttrell et al., 1999) . Agonist stimulation of the b 2 AR leads to the rapid recruitment of b-arrestin 1 that carries with it to the receptor activated c-Src (Figure 2) . The b-arrestin 1-c-Src interaction involves interactions with both the SH3 domain and the SH1 (catalytic) domain (Luttrell et al., 1999; Miller et al., 2000) . Blocking the b-arrestin-c-Src interaction with mutant forms of b-arrestin impairs b 2 AR stimulated ERK activation in 293 cells via mechanisms that appear distinct from those involved in regulating receptor internalization. The b-arrestin mediated interaction with c-Src has provided the ®rst evidence that the roles of b-arrestins are not limited to their roles in turning o receptor signaling via desensitization and internalization, but are also involved in recruiting signaling molecules to the receptor.
Recently the physiological roles of the b-arrestin-cSrc complex in signaling have been further expanded. The neurokinin-1 (NK-1) receptor is a Gq/11 coupled receptor, which is similar to the b 2 AR in that agonist stimulation of the receptor leads to the recruitment of b-arrestin and c-Src (DeFea et al., 2000a) . As is the case for the b 2 AR this recruitment of b-arrestin and cSrc is involved in GPCR mediated ERK activation. Stimulation of NK-1 receptors leads to the formation of b-arrestin/c-Src complexes that can be isolated by both co-immunoprecipitation and gel ®ltration and visualized by confocal microscopy. Interestingly, these b-arrestin-c-Src complexes also contain ERK, suggesting a broader role for b-arrestins in regulating the assembly of ERK activation complexes on the GPCR (see next section). The roles of b-arrestin in recruiting non-receptor tyrosine kinases also involve other src family members. In neutrophils, there is a correlation between the doses of interleukin-8 (IL-8) that stimulate granule release and that stimulate b-arrestin dependent internalization of the CXCR1 receptor. This IL-8 dependent granule release is mediated by b-arrestin binding to two src family members, HCK and c-Fgr (Barlic et al., 2000) . This neutrophil dependent granule release may involve a separate signaling pathway, a pathway that does not involve ERK activation.
Other mechanisms for GPCR-mediated c-Src activation have been recently demonstrated, including the direct recruitment of c-Src to the b 3 AR (Cao et al., 2000) . The b 3 AR is unusual among GPCRs because it is neither serine/threonine phosphorylated by Gprotein receptor kinases, nor does it bind b-arrestin. However, in both the third intracellular loop and in the carboxyl tail of the b 3 AR, there are proline rich sequences, not found in most GPCRs, which appear to directly interact with the SH3 domain of c-Src. Mutations of these proline rich sequences do not disrupt signaling by the classical second messenger generating system adenylyl cyclase, but they do disrupt the ability of the receptor to bind c-Src and to activate the ERK cascade. Thus, the b 3 AR appears to represent a distinct evolutionary step, a receptor that does not bind b-arrestin or internalize, but in which the structural elements required to recruit c-Src are contained within the receptor itself. In addition to the b 3 AR, there are several other GPCRs which contain proline rich regions in their third intracellular loops and carboxyl tails including the D 4 dopamine receptor, the b 1 AR, and the a 2A AR. It remains to be seen whether these other receptors also directly recruit and activate c-Src.
In addition, it has been recently reported that activated forms of two Ga subunits, Gai and Gas directly interact with and activate c-Src via the catalytic domain of the kinase (Ma et al., 2000) . While overexpression of constitutively active forms of either of these G-proteins leads to an increase in whole cell tyrosine phosphorylation, the potential role of this Figure 2 Role of c-Src-b-arrestin complexes and endocytosis in GPCR mediated ERK activation. Signals normally associated with desensitizing GPCR signaling, especially by the b 2 AR, are also involved in receptor signaling in two ways. First, agonist activation and subsequent serine/threonine phosphorylation of the receptor by G-protein coupled receptor kinases (GRKs) leads to the recruitment of the adapter protein b-arrestin, which brings with it c-Src. Although poorly understood, c-Src is required for GPCR mediated activation of the ERK cascade, and the b-arrestin/c-Src interaction with the receptor facilitates activation of downstream signaling components. Second, transactivation dependent ERK activation involves clathrin mediated endocytosis at a step downstream of Raf-activation. Although in most cases, both the GPCR and the RTK are internalized via clathrin coated pits, internalization of the GPCR itself is not required for this pathway of ERK activation. One hypothesis for the requirement for clathrin mediated internalization is that clathrin coated pits may serve as signaling microdomains, bringing many of the components of the ERK cascade into close proximity to one another interaction in GPCR mediated activation of ERK activation remained to be determined.
b-arrestin ± a novel MAPK scaolding protein
With the discovery that b-arrestin can recruit and activate c-Src came the ®rst evidence that b-arrestin is not only involved in`turning o' receptor signaling through its roles in desensitizing and internalizing GPCRs but also has additional roles in`turning on' signaling to the ERK cascade. These ®ndings have expanded the role of b-arrestin from that of a protein which helps link agonist-occupied receptors to the clathrin coated pit machinery to that of a adapter protein which facilitates interactions of signaling components with each other. Recently, b-arrestins have been found to do more than act as an adapter protein, they are now known to act as a scaolding protein.
Scaolding proteins subserve three important functions. First, they ensure that the proteins in a signaling pathway are maintained in the correct subcellular location. This will, for instance, keep proteins that have nuclear substrates out of the nucleus until activated by the proper signal. Second, they bring the proteins in a signaling cascade into close proximity with one another, which facilitates the sequential activation of the proteins. Bringing sequentially acting kinases into close proximity may help to catalyze the activation of the downstream kinases. The third role of scaolds is to ensure speci®city of signaling cascades, bringing into close proximity only those kinases that lead to the appropriate downstream signals. This colocalization may also enhance mutual interactions between the kinases and thus enhance signaling eciency. In the case of MAPK cascades, scaolds help to ensure that the proper MAPKKK, MAPKK, and MAPK are activated. Recently, b-arrestin has been shown to act as a scaold in two dierent MAPK cascades, an ERK cascade (DeFea et al., 2000a,b) and a JNK cascade (McDonald et al., 2000) .
For several years, scaolding proteins have been known to play a central role in MAPK signaling, especially in yeast. One of the best understood of the yeast scaold proteins is the S. cerevisiae protein STE5. In response to the mating pheromones a or a, the pheromone receptor, a GPCR, is activated. This leads to the Gbg dependent activation of a MAPK cascade. Speci®cally, activated Gbg recruits the scaolding protein STE5 to the plasma membrane. STE5 brings with it the MAPKKK, STE11, the MAPKK, STE7, and one of two MAPKs, Fus3 or Kss1 (Choi et al., 1994) . Although it is not precisely clear how Gbg activates STE11, activation may involve another kinase that also interacts with STE5, STE20 which in turn activates STE11. However, following STE11 activation, STE7 and either Fus3 or Kss1 are activated leading to transcriptional activation.
The ®rst mammalian scaolds were discovered, not for the ERK cascade, but rather the JNK cascade. Like the ERK cascade, the JNK cascade involves a MAPKKK (such as ASK-1 or MLK3), a MAPKK (such as MKK4), and a MAPK (such as JNK1). JIP-1, the ®rst mammalian MAPK scaolding protein was identi®ed in a yeast two hybrid screen for JNK interacting proteins (Whitmarsh et al., 1998) . Like other scaolding proteins, JIP-1 binds only to selective MAPKKKs (MLK) and MAPKKs (MKK7) (Yasuda et al., 1999) .
Following the discovery that b-arrestin/c-Src played a central role in ERK activation by the b 2 AR, it became apparent that b-arrestins might interact with other novel signaling proteins. In a yeast two hybrid screen using b-arrestin2 as bait, the MAPK, JNK3 was isolated (McDonald et al., 2000) and con®rmed in coimmunoprecipitation studies from whole brain lysates. Like the JIP1 scaold, b-arrestin2 immunoprecipitates from COS-7 cells also contain in addition to JNK3, a MAPKKK, ASK1, and a MAPKK, MKK4. This barrestin2 scaold is highly selective because b-arrestin2 (but not b-arrestin1) markedly facilitates the ASK-1 dependent activation of JNK3, but not JNK1. Interestingly, transfection of b-arrestin2 leads to the cytosolic retention of JNK3 (Figure 3) , while stimulation of cells expressing the angiotensin II Type 1A receptor leads to both JNK3 activation and to the colocalization of activated JNK3 and b-arrestin2 in cytosolic vesicles (Figure 3 ). This suggests that GPCR stimulation of JNK3 may promote phosphorylation of cytosolic, rather than nuclear targets. Thus, b-arrestins ful®ll all of the criteria of scaolding proteins in the JNK3 cascade. They maintain the kinases in a speci®c subcellular location, they help to colocalize the MAPKKK, the MAPKK, and the MAPK, they facilitate the activation of the MAPK, and they speci®cally activate JNK3, but not the two other known JNKs, JNK1 or JNK2. Notably, the b-arrestin/ JNK3 scaold is the ®rst mammalian scaold that, like the STE5 scaold in yeast, is receptor regulated.
In addition to serving as a scaold in the JNK3 cascade, b-arrestins also serve as scaolds in the ERK cascade. Agonist stimulation of the proteinase activated receptor-2 (PAR-2) leads to the formation of a large complex, including not only the receptor, and barrestin, but also the MAPKKK, raf-1, and activated ERK (DeFea et al., 2000b) . In similar experiments performed with the substance P activated NK-1 receptor, c-Src and ERK-1 were detected in complex with the receptor, while raf-1 was not detected, suggesting that the precise composition of the signaling complex depends upon both the GPCR and the barrestin that are involved. Of note, b-arrestin-dependent ERK activation by the PAR-2 and the NK-1 receptor also leads to dierent subcellular localization of the MAPK. The case of the PAR-2 appears similar to the b-arrestin-JNK3 complex. Both b-arrestin and activated ERK are retained in the cytosol, just as both b-arrestin and activated JNK3 are localized outside of the nucleus. However, in cells expressing the NK-1 receptor, the ERK, once activated translocates to the nucleus without b-arrestin. These ®nding suggest novel roles for b-arrestins in regulating the substrate speci®city of multiple MAPKs by restricting their localization to dierent compartments of the cell.
Conclusions
In contrast to the classical roles of GPCRs as minuteto-minute regulators of intermediary metabolism, it is growing increasingly apparent that heptahelical receptors play vital roles in the longer term regulation of cellular physiology, including such processes as hypertrophy, migration, proliferation and apoptosis. In studying these new roles, recent discoveries have highlighted the metalloprotease-dependent regulation of RTKs and the involvement of`desensitized' barrestin-GPCR complexes in scaolding components of several MAPK cascades.
The physiologic signi®cance of these novel signaling mechanisms remain to be delineated. Certainly, the predominant mechanism(s) employed in any given cell type will be determined by the speci®c complement of GPCRs and the available cellular machinery (e.g. EGFR, JNK isoforms). More fundamentally, however, the apparent redundancy of signaling mechanisms may represent the means for GPCRs on the cell surface to control both the timing of MAPK activation and the spatial distribution of activated MAPKs within the cell. This combination of short term versus long term stimulation, combined with the substrate speci®city imposed by spatial localization of the MAPKs may ultimately dictate the nature of the cellular response. et al., 2000) . In the absence of agonist, b-arrestin retains JNK3 in the cytosol. Agonist stimulation of the angiotensin II type 1A receptor leads to both the activation of JNK3 and the recruitment of the GPCR, b-arrestin and activated JNK3 to vesicles within the cell. Activated JNKs are most well known for their roles in stimulating gene transcription. However, it is likely that they, like ERKs, have cytosolic substrates and that the b-arrestin scaold targets activated JNK3 to the proper subcellular localization in order to facilitate the interaction with these non-nuclear substrates
